Immunogenic cell death in a combined synergic gene- and immune-therapy against cancer.
Mesenchymal stem cells
cancer
cyclophosphamide
immunological cell death
suicide gene
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
21
08
2019
accepted:
10
09
2019
entrez:
20
11
2019
pubmed:
20
11
2019
medline:
20
11
2019
Statut:
epublish
Résumé
It was previously demonstrated that engineered mesenchymal stem cells (MSCs) which express a high level of a very efficient modified gene CYP2B6* (CYP2B6TM-RED) acting as a suicide gene (MSC-2B6*) in combination with cyclophosphamide (CPA) constitute a powerful cell/gene therapy approach for solid tumors. In murine models, this combination led to tumor eradication and triggered a durable immune response against tumoral cells, which prevented recurrence and metastasis. The first goal, in this work, was to determine whether the mechanism of tumor cell death caused by CPA metabolites could explain the appearance of this anti-tumor immune response.
Identifiants
pubmed: 31741770
doi: 10.1080/2162402X.2019.1667743
pii: 1667743
pmc: PMC6844315
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1667743Informations de copyright
© 2019 The Author(s). Published by Taylor & Francis.
Références
J Cell Sci. 2004 Jun 1;117(Pt 13):2805-12
pubmed: 15169837
Mol Pharmacol. 2008 Apr;73(4):1122-33
pubmed: 18212249
Nat Rev Clin Oncol. 2009 Nov;6(11):638-47
pubmed: 19786984
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Cancer Res. 2012 Jul 15;72(14):3439-44
pubmed: 22761338
Cell Death Differ. 2014 Jan;21(1):79-91
pubmed: 23852373
Oncoimmunology. 2014 Dec 13;3(9):e955691
pubmed: 25941621
Cell Death Differ. 2014 Jan;21(1):39-49
pubmed: 23832118
Immunol Rev. 2017 Nov;280(1):126-148
pubmed: 29027218
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Nat Rev Immunol. 2014 Mar;14(3):166-80
pubmed: 24481336
EMBO J. 2012 Mar 7;31(5):1062-79
pubmed: 22252128
Cardiovasc Intervent Radiol. 2018 Jan;41(1):153-162
pubmed: 29090347
J Exp Med. 2005 Oct 3;202(7):919-29
pubmed: 16186184
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
J Control Release. 2016 Oct 10;239:82-91
pubmed: 27565211
Adv Physiol Educ. 2013 Dec;37(4):273-83
pubmed: 24292902
Cell Death Dis. 2013 Dec 12;4:e966
pubmed: 24336086
Cell Cycle. 2009 Nov 15;8(22):3723-8
pubmed: 19855167
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Front Immunol. 2015 Apr 24;6:187
pubmed: 25964783
Immunol Rev. 2007 Dec;220:22-34
pubmed: 17979837
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Oncoimmunology. 2015 Feb 18;4(4):e1005521
pubmed: 26137402
Front Immunol. 2015 Nov 20;6:588
pubmed: 26635802
Cancer Res. 2011 Feb 1;71(3):768-78
pubmed: 21156650
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
pubmed: 22301798
EMBO J. 2009 Mar 4;28(5):578-90
pubmed: 19165151
Cancer Gene Ther. 2005 May;12(5):497-508
pubmed: 15746946
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Immunol Rev. 2001 Aug;182:18-32
pubmed: 11722621
Biochimie. 2014 Oct;105:4-11
pubmed: 24977933
Curr Gene Ther. 2014;14(3):236-46
pubmed: 24766134
Cancer Immunol Immunother. 2007 May;56(5):641-8
pubmed: 16960692
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53
pubmed: 17255288
Mol Med. 2016 Sep;22:12-21
pubmed: 26837069
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Int J Cancer. 2013 Aug 1;133(3):624-36
pubmed: 23364915
Cancer Treat Rev. 2016 Jan;42:3-9
pubmed: 26620820
Cell Death Differ. 2009 Jan;16(1):175-83
pubmed: 18846108
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7
pubmed: 20547845
Biochem Biophys Res Commun. 2006 May 12;343(3):684-91
pubmed: 16563349
J Biol Chem. 2007 Sep 28;282(39):28749-58
pubmed: 17627942
Cancer Immunol Immunother. 2012 Mar;61(3):353-62
pubmed: 21915801
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765